Context Therapeutics Inc. (NASDAQ:CNTX) Stock Has Average Target Price of $6.40

Context Therapeutics Inc. (NASDAQ:CNTX) has been given an average recommendation of “Hold” by the nine ratings firms that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $6.40.

A number of equities research analysts have issued reports on the stock. Weiss Ratings raised shares of Context Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, October 15th. Zacks Research lowered Context Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, October 12th. Citigroup reiterated an “outperform” rating on shares of Context Therapeutics in a research report on Thursday, August 6th. Wall Street Zen lowered Context Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 20th. Finally, Lifesci Capital lowered Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th.

Context Therapeutics Stock Up 3.0%

NASDAQ CNTX opened at $0.19 on Friday. The firm has a market cap of $17.78 million, a P/E ratio of -0.40 and a beta of 1.77. The company’s 50 day moving average is $0.30 and its 200-day moving average is $1.42. Context Therapeutics has a 12-month low of $0.18 and a 12-month high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.06). Equities analysts expect that Context Therapeutics will post -0.45 EPS for the current year.

Institutional Investors Weigh In On Context Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. increased its holdings in Context Therapeutics by 8,907.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 671,074 shares of the company’s stock worth $202,000 after acquiring an additional 663,624 shares during the period. Squarepoint Ops LLC purchased a new stake in Context Therapeutics in the 2nd quarter worth approximately $29,000. Two Sigma Securities LLC boosted its holdings in Context Therapeutics by 388.7% in the 2nd quarter. Two Sigma Securities LLC now owns 61,444 shares of the company’s stock valued at $34,000 after purchasing an additional 48,871 shares during the period. Bank of America Corp DE bought a new position in Context Therapeutics in the 2nd quarter valued at $30,000. Finally, ADAR1 Capital Management LLC bought a new position in Context Therapeutics in the 2nd quarter valued at $416,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc (NASDAQ:CNTX) is a clinical-stage biotechnology company focused on developing targeted immunotherapies for solid tumors. The company’s approach is centered on T-cell-engaging bispecific antibodies, which are designed to direct the body’s immune cells toward cancer cells expressing specific tumor-associated antigens.

Context’s lead program is CTIM-76, an investigational bispecific antibody that targets Claudin 6 (CLDN6) on tumor cells and CD3 on T cells. The program is being developed for patients with CLDN6-positive advanced solid tumors, including ovarian, endometrial, testicular and other cancers.